Advocacy

ASHG supports the nomination of Eric Lander, PhD, to lead the Office of Science and Technology Policy (OSTP).  The announcement of the new team at the dawn of President Biden’s presidency, and elevating the Director of OSTP to a Cabinet position, is a positive sign that science, and scientists, will have a core role in... Read More

In 2021, the genetics and genomics community needs to communicate to policymakers how the field of human genetics and genomics is transforming biomedical research and medicine, including its essential role in combatting COVID-19. This is important for ensuring that policies enable a thriving scientific enterprise and provide resources for research advances. Related: AJHG Perspective: How... Read More

The first few weeks of 2021 have brought numerous changes to the federal policy landscape, including the beginning of the new Biden Administration, a new Congress with a Democratic majority in both the Senate and the House of Representatives, and the deadly January 6 attack on the U.S. Capitol and its fallout.  While these events... Read More

On September 25, ASHG hosted a virtual Forum with several members of the International Commission on the Clinical Use of Human Germline Genome Editing. The Forum was chaired by Charles Rotimi of NIH, and speakers shared findings from the Commission’s final report on Heritable Human Genome Editing (HHGE), which was released earlier that month. The... Read More

Each year, Congress is tasked with setting budgets across the federal government, including for the National Institutes of Health (NIH), before October 1, the beginning of the new fiscal year. However, this month we passed the October 1 deadline without Congress passing legislation to accomplish this for Fiscal Year 2021. This means that the size... Read More